- Jonathan Dickinson joins Innate on November 1 and brings
broad experience from leadership roles in biotech and big
pharma
- Current interim CEO and co-founder Hervé Brailly will
support the transition
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that its
supervisory Board has appointed Jonathan Dickinson as the Company’s
new Chief Executive Officer (CEO) and Chairman of the Executive
Board, effective November 1, 2024. Jonathan Dickinson succeeds
Hervé Brailly, co-founder of the Company, who was interim CEO,
during the search process.
Jonathan Dickinson most recently served as Executive Vice
President and General Manager, Europe at Incyte, a role he held
since 2016. Prior to Incyte, he gained significant leadership
experience through several senior positions at ARIAD
Pharmaceuticals, a US oncology focused biotechnology company and
Bristol-Myers Squibb. This followed a distinguished 13-year tenure
at Hoffmann-La Roche, where he was instrumental in driving the
success of several of the company’s flagship oncology therapies.
Mr. Dickinson began his career at Novartis, holding roles of
increasing responsibility within the oncology and endocrinology
divisions. He holds a Bachelor of Science degree in Genetics and a
Master of Business Administration from the University of
Nottingham.
Dr. Hervé Brailly, PhD, current interim CEO, will stay for the
next few months in an advisory role to ensure a smooth transition.
It will be proposed that Dr. Brailly joins the Board at the next
opportunity.
Irina Staatz-Granzer, Chairwoman of the Supervisory Board,
commented: “I am very pleased to announce the appointment of
Jonathan Dickinson as our new Chief Executive Officer. Jonathan is
a distinguished industry leader whose extensive experience in the
biotechnology and pharmaceutical sectors, combined with his proven
leadership abilities, make him the ideal choice to lead Innate
Pharma. We are confident that his vision and strategic acumen will
drive the advancement of our innovative immuno-oncology pipeline
and position the Company for continued success in the next phase of
its growth.”
Jonathan Dickinson, new Chief Executive Officer of Innate
Pharma said: “I am excited to join Innate Pharma, a pioneer in
harnessing the power of the immune system to fight cancer, at a
pivotal moment in the Company’s evolution. With a diverse pipeline
spanning early-stage ADCs and ANKET® NK-cell engagers to more
advanced programs like lacutamab and monalizumab, I look forward to
working with the talented team at Innate to drive the Company’s
innovative therapies forward. Together, we will continue to advance
Innate Pharma’s mission to deliver transformative treatments for
patients while creating value for employees, shareholders, and all
our stakeholders.”
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through three therapeutic approaches: monoclonal antibodies,
multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK
cell Engager Therapeutics) proprietary platform and Antibody Drug
Conjugates (ADC).
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, several ANKET® drug candidates to
address multiple tumor types as well as IPH4502 a differentiated
ADC in development in solid tumors.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
This press release contains certain forward-looking statements,
including those within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995. The
use of certain words, including “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “may,” “might,” “potential,”
“expect” “should,” “will,” or the negative of these and similar
expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s reliance on third parties to manufacture its product
candidates, the Company’s commercialization efforts and the
Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2023, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public by
the Company. References to the Company’s website and the AMF
website are included for information only and the content contained
therein, or that can be accessed through them, are not incorporated
by reference into, and do not constitute a part of, this press
release.
In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any
specified time frame or at all. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241013010417/en/
For additional information, please contact:
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Grafico Azioni Innate Pharma (EU:IPH)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Innate Pharma (EU:IPH)
Storico
Da Nov 2023 a Nov 2024
